The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
Official Title: FACT: Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy; an Open Randomized, Comparative, Phase III Multicentre Study in Postmenopausal Women With Hormone Receptor Positive Breast Cancer in First Relapse After Primary Treatment of Localized Tumor.
Study ID: NCT00256698
Brief Summary: The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive women with first relapse of breast cancer.
Detailed Description:
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Research Site, Brampton, , Canada
Research Site, Halifax, , Canada
Research Site, Kingston, , Canada
Research Site, Ontario, , Canada
Research Site, Toronto, , Canada
Research Site, San Jose, , Costa Rica
Research Site, Hameenlinna, , Finland
Research Site, Turku, , Finland
Research Site, Avignon, , France
Research Site, Caen, , France
Research Site, Creteil, , France
Research Site, Grenoble, , France
Research Site, La Chaussee Saint Victor, , France
Research Site, Perigueux, , France
Research Site, Perpignan, , France
Research Site, Saint Cyr Sur Louire, , France
Research Site, Toulouse, , France
Research Site, Augsburg, , Germany
Research Site, Dusseldorf, , Germany
Research Site, Erlangen, , Germany
Research Site, Frankfurt, , Germany
Research Site, Gifhorn, , Germany
Research Site, Grosshadern, , Germany
Research Site, Halle, , Germany
Research Site, Hamburg, , Germany
Research Site, Hannover, , Germany
Research Site, Heidelberg, , Germany
Research Site, Ingolstadt, , Germany
Research Site, Kassel, , Germany
Research Site, Kiel, , Germany
Research Site, Koln, , Germany
Research Site, Leipzig, , Germany
Research Site, Leverkusen, , Germany
Research Site, Magdeburg, , Germany
Research Site, Mannheim, , Germany
Research Site, Marburg, , Germany
Research Site, Munchen, , Germany
Research Site, Rostock, , Germany
Research Site, Trier, , Germany
Research Site, Ulm, , Germany
Research Site, Ziwicken, , Germany
Research Site, Guatemala, , Guatemala
Research Site, Reykjavik, , Iceland
Research Site, Como, , Italy
Research Site, Fabriano, , Italy
Research Site, Ferrara, , Italy
Research Site, Firenze, , Italy
Research Site, Lugo, , Italy
Research Site, Milano, , Italy
Research Site, Taormina, , Italy
Research Site, Treviglio, , Italy
Research Site, Vicenza, , Italy
Research Site, Drammen, , Norway
Research Site, Ilesund, , Norway
Research Site, Oslo, , Norway
Research Site, Porsgrunn, , Norway
Research Site, Stavanger, , Norway
Research Site, Troms, , Norway
Research Site, Trondheim, , Norway
Research Site, Cascais, , Portugal
Research Site, Coimbra, , Portugal
Research Site, Lisboa, , Portugal
Research Site, Santa Maria da Feira, , Portugal
Research Site, Halmstad, , Sweden
Research Site, Helsingborg, , Sweden
Research Site, Kalmar, , Sweden
Research Site, Karlskrona, , Sweden
Research Site, Kristianstad, , Sweden
Research Site, Link'ping, , Sweden
Research Site, M'lndal, , Sweden
Research Site, Malm, , Sweden
Research Site, Norrk'ping, , Sweden
Research Site, Skelleftea, , Sweden
Research Site, Skovde, , Sweden
Research Site, Stockholm, , Sweden
Research Site, Sunderbyn, , Sweden
Research Site, Sundsvall, , Sweden
Research Site, Umea, , Sweden
Research Site, V'rnamo, , Sweden
Research Site, V'stervik, , Sweden
Research Site, Varberg, , Sweden
Research Site, Ankara, , Turkey
Research Site, Edirne, , Turkey
Research Site, Gaziantep, , Turkey
Research Site, Istanbul, , Turkey
Name: Roger Henriksson, MD
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR